The importance of methionine to cell function is indicated by its critical role in protein synthesis, S-adenosylmethionine-dependent methyl transfer reactions, and polyamine biosynthesis (8) . The demands upon the methionine pool from these processes make salvage of this energetically "expensive" amino acid advantageous for cellular function. One such salvage pathway is the remethylation of homocysteine in a process which involves vitamin B12 and 5-methyltetrahydrofolate (4) . Another methionine salvage pathway involves the recycling of methionine from 5'-methylthioadenosine (MTA), which is important for conserving the amino acid during the synthesis of the polyamines spermidine and spermine ( Fig. 1) (29, 33) .
Two distinct mechanisms exist for the salvage of methionine from MTA. In mammalian cells (2, 3) and some microorganisms (31) , MTA is degraded in one step to adenine and 5-methylthioribose-1-phosphate (MTR-1-P) by MTA phosphorylase (26) . In other microbes (including some members of the family Enterobacteriaceae), MTA is catabolized in two steps: first to adenine and MTR via MTA nucleosidase (9) , followed by conversion of MTR to MTR-1-P via MTR kinase (10) . In both cases, MTR-1-P is synthesized, but by two distinct metabolic pathways. In many procaryotic and eucaryotic cells, MTR-1-P is then recycled to methionine via the intermediates 1-phospho-5-S-methylthioribulose (13, 32), 1-phospho-2,3-diketo-5-S-methylthiopentane (12), and 2-keto-4-methylthiobutyrate (1, 30) .
Since MTR kinase is not present in human cells and because it is important in microbial methionine recycling, it is a logical target for chemotherapeutic drug design (27, 28) . In a recent study, we showed that 5-trifluoromethylthioribose (TFMTR), a structural analog of MTR, exerts potent inhibitory effects on Klebsiella pneumoniae, an MTR kinase-* Corresponding author.
containing organism (11, 14) . Although the mode of action of TFMTR against K. pneumoniae has not been delineated, it is believed that TFMTR is converted within organisms to a toxic product (e.g., trifluoromethionine or carbonothioic difluoride) via the methionine salvage pathway. If this is the case, one might expect inhibition of de novo synthesis of methionine to enhance the inhibitory activity of TFMTR toward MTR kinase-containing microbes. Presumably, inhibition of de novo methionine synthesis would increase reliance on the methionine salvage pathway for maintenance of methionine levels, thereby leading to increased conversion of TFMTR to toxic products. In order to investigate this possibility and to gain insight into the mode of action of TFMTR, we examined the effect of pairing TFMTR with three inhibitors of microbial methionine synthesis. These compounds (1,2,4-triazole, azaserine, and propargylglycine) interfere with methionine synthesis through distinctly different mechanisms ( Fig. 1) (20, 23, 25) . In this report, we show that these agents act synergistically with TFMTR in inhibiting the growth of K. pneumoniae.
MATERIALS AND METHODS
Chemicals. Azaserine (O-diazoacetylserine), DL-propargylglycine, and 1,2,4-triazole were purchased from Sigma Chemical Co. (St. Louis, Mo.). TFMTR was synthesized as described previously (14) . (NH4)6Mo7024 (5 x 10' M); the medium was adjusted to pH 7.2. Dose inhibition studies were conducted in 5-ml cultures inoculated with -104 cells per ml and maintained in a rotary shaker incubator at 37°C. Growth was monitored by optical density at 470 nm 12 to 15 h after incubation or after control cultures reached an optical density of -0.4. Isoboles representing the activity of drug mixtures were performed and analyzed as described by Hewlett (16) . Briefly, TFMTR and 1,2,4,-triazole, azaserine, or propargylglycine were serially diluted so that the organisms were simultaneously exposed to drug mixtures. The abilities of the various drug combinations to inhibit growth by 50% (IC50) relative to control values were measured. When combined and plotted graphically, the results yielded an isobologram. As described by Hewlett, isoboles for two separately active drugs resemble a straight line for additive action, a convex line for subadditive action, and a concave line for potentiation (16) .
RESULTS
Effect of methionine on the inhibitory action of TFMTR. In order to gain insight into the mechanism of action of TFMTR, we tested the ability of methionine to reverse the inhibitory effect of TFMTR. K. pneumoniae was cultured in defined medium containing 1 ,uM TFMTR and different amounts of methionine. The organisms were inoculated at a density of -104/ml and incubated for 12 to 15 h at 37°C. In the absence of added methionine, TFMTR totally inhibited cell growth. Less than 10% of control values was observed when methionine was added at 10 ,uM in the presence of TFMTR. Increasing the concentration of methionine to 100 ,uM restored growth to nearly 60% of control. The inhibitory action of TFMTR was completely abrogated by the addition of 1,000 ,uM methionine. Other amino acids, such as glycine, isoleucine, serine, threonine, aspartic acid, glutamic acid, and glutamine, had no effect on the antimicrobial action of TFMTR (data not shown). The fact that methionine reverses the antibacterial activity of TFMTR is consistent with the theory that TFMTR blocks cell growth by exploiting methionine recycling. Furthermore, this finding suggests that blocking microbial methionine biosynthesis will enhance the inhibitory action of TFMTR.
Synergy between TFMTR and inhibitors of methionine biosynthesis. 1,2,4-Triazole is an inhibitor of O-acetylserine sulfhydrylase, the final step in microbial cysteine biosynthesis ( Fig. 1) (25) . Accordingly, the antimicrobial effect of 1,2,4-triazole can be reversed by the addition of cysteine but not cystathionine or homocysteine (25 and unpublished data). We tested the ability of 1,2,4-triazole to augment the antimicrobial activity of TFMTR. As described by Gianotti et al. (14) , the clinical strain of K. pneumoniae used in our studies contains MTR kinase, actively salvages methionine from MTA in vivo, and is very sensitive to the effects of TFMTR, exhibiting an IC50 in the submicromolar range. As shown in Fig. 2A, 1,2 the joint action ratio for the drug combination was calculated to be 2.5. Azaserine is a substrate for O-acetylserine sulfhydrylase (Fig. 1) . Upon reaction of azaserine with this enzyme, diazoacetate, a highly reactive and toxic product, is formed (23) . Unlike 1,2,4-triazole, cysteine is unable to completely reverse the inhibitory effect of azaserine (unpublished data), presumably because of the production of toxic diazoacetate. Studies with TFMTR and azaserine demonstrated a striking synergy (Fig. 2B) . The IC50 for azaserine alone against K. pneumoniae was 2.0 jxM. At all drug ratios, the amount of either drug required to produce 50% inhibition was less with the combination than with either drug alone and became minimal when 0.05 ,uM TFMTR was combined with 0.25 ,M azaserine. The degree of potentiation for TFMTR and azaserine measured as the joint action ratio was 3.6.
Propargylglycine is an irreversible inhibitor of cystathionine y-synthase (20) , a pyridoxal phosphate-dependent enzyme involved in microbial methionine synthesis (19) (Fig.  1) . The growth inhibitory effects of propargylglycine are reversed by methionine (7, 20) . In our studies, -375 ,uM propargylglycine was required to inhibit Klebsiella growth by 50%. As shown in Fig. 2C , combining as little as 0.1 ,uM TFMTR with 20 ,M propargylglycine produced the same degree of growth inhibition. All points from the TFMTRpropargylglycine combinations used in the study fell well below the line of addition. The degree of potentiation between the two drugs was calculated to be 3.2.
DISCUSSION
Microbial biosynthesis of cysteine and methionine proceeds along a branched convergent pathway in one arm of which sulfate is reduced to sulfide while serine is acetylated to O-acetylserine ( Fig. 1) (19, 23) . The final step consists of formation of cysteine from sulfide and O-acetylserine by the enzyme O-acetylserine sulfhydrylase (24) . Methionine is then synthesized from cysteine via cystathionine in a sequence of reactions catalyzed by cystathionine -y-synthase (22) , cystathionine ,B-lyase (15) , and methionine synthase (4). Thus, unlike mammalian cells, which synthesize cysteine from methionine, enteric bacteria derive methionine from cysteine (19) .
In this study, we employed three different agents which perturb microbial cysteine and methionine biosynthesis to test the ability of these compounds to act in synergy with TFMTR. 1,2,4-Triazole blocks cysteine and methionine production through competitive inhibition of O-acetylserine sulfhdrylase (23) , while azaserine (0-diazoacetylserine) serves as an alternate substrate for the enzyme, giving cysteine and toxic diazoacetate as products. Propargylglycine blocks methionine biosynthesis through irreversible inactivation of cystathionine -y-synthase (20) . Our results show that all three compounds act synergistically with TFMTR to inhibit the growth of K. pneumoniae. In fact, the degree of synergy between TFMTR and one of the compounds tested (azaserine) approaches that observed between trimethoprim and the sulfonamides (6) . Taken together, these findings are consistent with the proposed modes of action of TFMTR, e.g., competitive inhibition of MTR kinase and/or conversion to a toxic product via the methionine recycling pathway.
A diverse group of drugs may similarly augment the action of TFMTR. For example, trimethoprim (a folate antagonist) acts to inhibit dihydrofolate reductase, resulting in a general depletion of reduced folate cofactors needed for synthesis of purines and thymidine as well as methionine (17, 18) . It is conceivable that the block in methionine production exerted by trimethoprim will potentiate TFMTR in a manner that is analogous to that of the drugs tested in this report. Inhibitors of polyamine biosynthesis (5) may also be useful in combination with TFMTR by virtue of their ability to block production of MTR (Fig. 1) . Theoretically, polyamine antagonists which block synthesis of spermidine and spermine will decrease intracellular levels of MTR and allow a higher rate of conversion of TFMTR to toxic products. Future work in this laboratory will test these possible drug combinations.
Chemotherapy employing multiple drugs with different modes of action is important to prevent the emergence of drug-resistant pathogens. Ideally, such drugs should act synergistically toward the elimination of the invading parasite. From the results presented here, it is clear that compounds which block microbial methionine metabolism act synergistically with TFMTR. Furthermore, the combination of TFMTR with an antagonist of microbial methionine synthesis provides a novel approach towards the control of infections caused by MTR kinase-containing pathogens.
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